New drug combo tested for Tough-to-Treat lung cancer
NCT ID NCT04691817
Summary
This study is testing whether combining two existing drugs, tocilizumab and atezolizumab, can help control advanced non-small cell lung cancer that has stopped responding to initial immunotherapy. It will enroll about 28 adults to check if the combination is safe and if it shrinks tumors or slows cancer growth. The main goal is to see how many patients' tumors respond to this new treatment approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER, NONSMALL CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Abramson Cancer Center of the University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.